Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
Date:5/8/2008

NEW YORK, May 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, May 12, 2008 at 8:30 a.m. EDT to discuss the first quarter 2008 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-800-723-6575 (U.S.), 1-785-830-1997 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
2. Keryx Biopharmaceuticals Receives Nasdaq Notification
3. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
4. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
5. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... and LONDON , May 23, 2016 ... Could See Frontage Boost Efficiency by 40% - Frontage ... - Frontage Enforce Quality, Compliance and Traceability Within the Bioanalytical ... with labs in the United States and ... to be deployed across its laboratory facilities. In addition to ...
(Date:5/23/2016)... ... 23, 2016 , ... Foresight Institute , a leading ... for the 2015 Foresight Institute Feynman Prizes. , These prestigious prizes, named ... for experiment and the other for theory in nanotechnology. Prof. Markus J. Buehler, ...
(Date:5/20/2016)... CA (PRWEB) , ... May 20, 2016 , ... The ... 10 of its most experienced veterinary clients have treated over 100 of their own ... edge technology to provide the highest level of care for their patients. , ...
(Date:5/20/2016)... NC (PRWEB) , ... May 20, 2016 , ... Korean ... suggesting that it may offer a new way to treat the disease. Surviving Mesothelioma ... it now. , Scientists from several Korean institutions based their mesothelioma study on ...
Breaking Biology Technology:
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
Breaking Biology News(10 mins):